Maciej Kawecki

Maciej Kawecki

Auto-generated profile, based on publicly available information

Maciej Kawecki

Maria Skłodowska Curie Memorial Cancer Centre, Warsaw, Poland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2021 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Open access
PDF file
ŁMŁukasz Mielczarek
Łukasz Mielczarek
ABAnna Brodziak
Anna Brodziak
PSPaweł Sobczuk
Paweł Sobczuk
MKMaciej Kawecki
Maciej Kawecki
ACAgnieszka Cudnoch-Jędrzejewska
Agnieszka Cudnoch-Jędrzejewska
Anna M. Czarnecka, MBAAnna M. Czarnecka, MBA
Anna M. Czarnecka, MBA
The introduction of novel targeted therapies during the last 2 decades has led to a significant improvement in patients' clinical outcomes with renal cell carcinoma. However, this improvement came at the price of a whole new spectrum of adverse events, including renal toxicity. Systemic treatment of patients with kidney neoplasms who often present with impairment of kidney function, even prior to treatment, poses an increasing diagnostic and therapeutic challenge for clinicians. Common lifestyle-related comorbidities, i.e., hypertension and diabetes, may contribute to further impairment of kidney function. The lack of official guidelines and the exclusion of patients with reduced kidney function from the clinical trials of recently approved drugs complicate the issue even further. Early detection and correct management of renal toxic effects are crucial to preserve kidney function and ensure the optimal administration of life-prolonging therapies. This review presents detailed information on the renal toxicities of three groups of drugs commonly used in renal cell carcinoma treatment: tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors, and immune checkpoint inhibitors. We outline the incidence and underlying mechanisms of renal adverse effects with a focus on patients on renal replacement therapy, as well as present suggestions for their management.

29 December 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
RIRolf Issels
Rolf Issels
SBStefan Boeck
Stefan Boeck
UPUwe Pelzer
Uwe Pelzer
UMUlrich Mansmann
Ulrich Mansmann
PGPirus Ghadjar
Pirus Ghadjar
JWJens Werner
Jens Werner